Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Immunology
Study Phase : Approved
Recipient : MEDUNIK CANADA
Deal Size : Not Applicable
Deal Type : Not Applicable
Médunik Canada's Ruzurgi® Now Available to Canadian Lambert-Eaton Myasthenic Syndrome Patients
Details : Médunik Canada has retained the services of Innomar, a leading specialty pharmaceutical service and patient support program provider, for the distribution of Ruzurgi® and management of its UnikAccess Patient Support Program.
Brand Name : Ruzurgi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 25, 2020
Lead Product(s) : Amifampridine Phosphate
Therapeutic Area : Immunology
Highest Development Status : Approved
Recipient : MEDUNIK CANADA
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
